Fundraising Fox
/Companies
Sign in

Pluristyx

Seattle, US · Washington corporation · 1 known investors

Find your way into Pluristyx

Sign up to see every warm intro you have to Pluristyx

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Pluristyx team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Pluristyx develops induced pluripotent stem cell (iPSC) technologies, including non-modified and genetically engineered cell lines, proprietary gene edits, and reprogramming platforms, along with related services. It provides these products and end-to-end development support to companies building cell and stem cell therapies.

BiotechDeep TechMedical Devices

Founders & leadership

BFBenjamin Fryer
Benjamin FryerCo-Founder and CEOBenjamin Fryer holds a PhD in pharmacology from the University of Pennsylvania and completed postdoctoral research at UPenn's Howard Hughes Laboratory; he brings nearly 25 years of experience in biopharmaceutical and cell therapy development across large pharmaceutical companies, startups, and academic institutions, and is co-founder and CEO of Pluristyx.
JC
Jason CarstensNamed on SEC filing
TC
Trent CarrierNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements

$9.8M disclosed across 1 round · 2026

▶$9.8MraisedJul 2026 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin FryerExecutive Officer, Director, Promoter
  • Jason CarstensExecutive Officer, Director
  • Trent CarrierDirector
Offering amount
$14.8M
Amount sold
$9.8M
First sale
Jul 2026
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

AbcamSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
IntechopenIntechOpen is an open access publisher of books and open science journals covering science, technology, and medicine, serving academics and researchers across interdisciplinary fields. It also operates a book series model with editorial-board-led topics and a custom manuscript submission and peer review platform.
Akadeum Life SciencesAkadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products. The company serves research, clinical trial, and therapeutic manufacturing environments requiring regulated cell separation products.

Companies working in the same space as Pluristyx.

In the news

Pluristyx Announces Major New Funding Round to Bolster Expansion Plans - Pluristyxpluristyx.com

Frequently asked questions

What does Pluristyx do?
Pluristyx develops induced pluripotent stem cell (iPSC) technologies, including non-modified and genetically engineered cell lines, proprietary gene edits, and reprogramming platforms, along with related services. It provides these products and end-to-end development support to companies building cell and stem cell therapies.
Who founded Pluristyx?
Pluristyx was founded by Benjamin Fryer.
Who are Pluristyx's investors?
Pluristyx's investors include BroadOak Capital Partners.
How much funding has Pluristyx raised?
Pluristyx has disclosed $9.8M raised across 1 round.
Where is Pluristyx headquartered?
Pluristyx is headquartered in Seattle, US.